103-palladium
Small moleculeexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2007 (NCT00450411)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetRadiodepletion
radiodepletion
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 103-palladium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00450411 | Phase 2 | May 1, 2007 | British Columbia Cancer Agency, National Cancer Institute (NCI), NRG Oncology, Radiation Therapy Oncology Group |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| British Columbia Cancer Agency | Academic/Hospital | 1 | 0 | 1 | 2007 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2007 |
| NRG Oncology | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Radiation Therapy Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2007 |
4 organizations
Page 1 / 1